Helus Pharma Secures $175M in Registered Direct Offering, Bolstering Cash Reserves for Clinical Pipeline
HELP sits 38% above its 52-week low of $4.81.
Summary
Helus Pharma announced a $175 million registered direct offering, dramatically increasing its cash reserves to $195.1 million and enabling continued advancement of its HLP003 Phase 3 and HLP004 Phase 2 clinical programs.
Key Events · Financing and Capital Events · HELP
-
Secured $175 Million in Capital
Helus Pharma completed a registered direct offering on October 31, 2025, issuing 22,277,750 common shares and 4,605,500 pre-funded warrants for gross proceeds of approximately $175 million. The offering was priced at $6.51 per share or pre-funded warrant.
-
Boosted Cash Position to $195.1 Million
As of December 31, 2025, the company's cash and cash equivalents totaled $195.1 million, a substantial increase from $93.9 million on March 31, 2025, primarily due to the recent capital raise.
-
Repaid Convertible Debentures
A portion of the offering proceeds was used to repay the remaining outstanding balance of $20.15 million in convertible debentures on November 3, 2025, including early repayment fees of $2.615 million.
-
Advancing Clinical Pipeline
The company continues to progress its HLP003 Phase 3 program for Major Depressive Disorder (MDD) and its HLP004 Phase 2 program for Generalized Anxiety Disorder (GAD), with topline data for HLP004 expected in Q1 2026.
Analysis · HELP · Life Sciences
This 6-K filing reveals a transformational capital raise for Helus Pharma, securing $175 million in gross proceeds through a registered direct offering. This massive infusion of capital, which significantly exceeds the company's stated market capitalization, fundamentally alters its financial position and provides a substantial runway for its critical drug development programs. The proceeds were used to repay outstanding convertible debentures and will fund the advancement of the HLP003 Phase 3 and HLP004 Phase 2 clinical trials, including anticipated topline data readouts. While highly dilutive, this financing is a lifeline for a clinical-stage biotech, ensuring its ability to execute its pipeline and pursue commercialization.
At the time of this filing, HELP was trading at $6.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $4.81 to $10.59. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.